Veru Inc (VERU)
NASDAQ:VERU
Want to see VERU full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reported meaningful clinical progress (positive Phase IIb functional results, active enrollment in a pivotal-feeding Phase IIb plateau study with interim readout expected Q1 2027) and materially improved near-term liquidity and expense trends. At the same time, Veru remains unprofitable, faces label and regulatory complexity (possible need for agent-specific studies or function/BMD endpoints), stiff competition from established GLP-1 players, and dependence on nonrecurring gains and an interim milestone for runway. On balance, the progress on clinical endpoints, the clear regulatory strategy contingencies, and improved cash position outweigh the operational and regulatory risks discussed.Company Guidance
Positive Phase IIb 'quality' study results on physical function
Enobosarm plus semaglutide demonstrated preservation of lean mass and physical function versus semaglutide alone. Enobosarm 3 mg + semaglutide produced a 59.8% relative reduction in the proportion of patients with ≥10% decline in stair-climb power versus placebo+semaglutide (p=0.0006). Enobosarm 6 mg + semaglutide produced a 44.1% relative reduction (p=0.051).
Phase IIb 'plateau' study initiated and on track
First patient enrolled March 9, 2026 in the double-blind, placebo-controlled Phase IIb plateau study (~200 patients ≥65 years, BMI ≥35). Interim analysis planned at 36 weeks and top-line interim results expected in Q1 2027; management reports enrollment rate as 'very pleased' and on track.
Clear regulatory path contingencies clarified
Company reiterated that incremental weight-loss ≥5% would anchor an efficacy claim for Phase III, with physical function and bone mineral density (BMD) able to support additional claims. If incremental weight loss <5%, functional endpoints or BMD may support approval — the current trials are designed to inform those pathways.
Large target market opportunity articulated
Management highlighted a sizable addressable market: >1 billion people with obesity globally, WHO estimate of 2.5 billion overweight/obese adults, ~30 million U.S. adults with obesity and low muscle mass (sarcopenic obesity), and ~41.5% obesity prevalence in patients ≥65 (≈20 million Medicare Part D enrollees estimated as potential patients).
Improved quarterly and six-month expense trends
R&D decreased to $3.1M from $3.9M quarter-over-quarter (≈20.5% decrease) and to $4.5M versus $9.6M year-to-date prior period (≈53.1% decrease). SG&A decreased to $4.1M from $5.2M quarter-over-quarter (≈23.1% decrease) and to $8.2M versus $10.4M year-to-date prior period (≈21.2% decrease), driven largely by lower share-based compensation and wind-down of the Phase IIb 'quality' study.
Improved near-term liquidity position
Cash, cash equivalents and restricted cash increased to $27.6M as of March 31, 2026 from $15.8M as of Sept 30, 2025 (≈+74.7%). Net working capital rose to $28.0M from $11.1M (~+152%). Net proceeds of ~$23.4M were raised from an Oct 31, 2025 underwritten public offering. Management expects cash to be sufficient to fund operations beyond the Phase IIb interim analysis.
Reduced operating cash burn and better quarter net loss
Cash used in operating activities for the 6 months ended March 31, 2026 was $15.1M versus $19.1M prior period (~21.0% reduction). Quarterly continuing-operations net loss improved to $3.1M ($0.13 per diluted share) from $7.9M ($0.54) in the prior-year quarter (~60.8% improvement).
VERU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VERU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $2.27 | $2.26 | -0.44% |
Feb 11, 2026 | $2.31 | $2.30 | -0.43% |
Dec 17, 2025 | $2.44 | $2.23 | -8.61% |
Aug 12, 2025 | $3.59 | $3.17 | -11.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Veru Inc (VERU) report earnings?
Veru Inc (VERU) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Veru Inc (VERU) earnings time?
Veru Inc (VERU) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VERU EPS forecast?
VERU EPS forecast for the fiscal quarter 2026 (Q3) is -0.32.